Andre Schuh
Overview
Explore the profile of Andre Schuh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lachaine J, Beauchemin C, Dodat F, Au Y, Evans W, Leber B, et al.
Acta Haematol
. 2024 Feb;
148(1):8-21.
PMID: 38382483
Introduction: Acute myeloid leukemia (AML) represents a significant burden for patients and their families, and to the healthcare system. This study estimated the total cost of illness associated with newly...
2.
Zhao D, Zhou Q, Zarif M, Eladl E, Wei C, Atenafu E, et al.
Leuk Res
. 2023 Sep;
134:107376.
PMID: 37690321
AML with CEBPA mutation and AML with in-frame bZIP CEBPA mutations define favorable-risk disease entities in the proposed 5th edition of the World Health Organization Classification (WHO-HAEM5) and the International...
3.
Renzi S, Algawahmed F, Davidson S, Langenberg K, Fuligni F, Ali S, et al.
Curr Oncol
. 2023 Jul;
30(7):5946-5952.
PMID: 37503586
gene fusion is a rare genetic rearrangement in a variety of malignancies, including myeloproliferative neoplasms (MPN), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). Here, we report the case...
4.
Zhao D, Zarif M, Zhou Q, Capo-Chichi J, Schuh A, Minden M, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370821
mutations are associated with extremely poor outcomes in acute myeloid leukemia (AML). The outcomes of patients with -mutated () AML after different frontline treatment modalities are not well established. Allogeneic...
5.
Murphy T, Zou J, Arruda A, Wang T, Zhao Z, Zheng Y, et al.
Haematologica
. 2023 Jun;
109(2):671-675.
PMID: 37345484
No abstract available.
6.
Hershenfeld S, Atenafu E, Chan S, Gupta V, Maze D, Schuh A, et al.
Acta Haematol
. 2023 Jun;
146(5):366-372.
PMID: 37315549
Introduction: Care for patients with acute myeloid leukemia (AML) is centralized in the Ontario single-payer public healthcare system, with intensive induction chemotherapy and clinical trials only offered at specialized cancer...
7.
Vasudevan Nampoothiri R, Tang K, Schuh A, Lam W, Maze D, Michelis F, et al.
Eur J Haematol
. 2023 Feb;
110(6):618-625.
PMID: 36732677
Background: Inconclusive cytogenetic analysis (IC) at baseline has been reported as a predictor of poor prognosis in patients with acute myeloid leukemia (AML). The mutational profile in this group of...
8.
Zhao D, Eladl E, Zarif M, Capo-Chichi J, Schuh A, Atenafu E, et al.
Cancer Med
. 2022 Nov;
12(6):6511-6522.
PMID: 36394085
Background: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) generally confers poor prognosis, however, patient outcomes are heterogeneous. The impact of TP53 allelic state and variant allele frequency (VAF) in AML-MRC...
9.
Zhao D, Zarif M, Eladl E, Capo-Chichi J, Smith A, Atenafu E, et al.
Leuk Res
. 2022 May;
118:106869.
PMID: 35636054
Background: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a prognostically diverse disease. Owing to its favourable prognosis, AML-MRC with mutated NPM1 (NPM1) diagnosed on the basis of multi-lineage dysplasia...
10.
Calvillo-Arguelles O, Schoffel A, Capo-Chichi J, Abdel-Qadir H, Schuh A, Carrillo-Estrada M, et al.
JACC CardioOncol
. 2022 May;
4(1):38-49.
PMID: 35492819
Background: Clonal hematopoiesis of indeterminate potential (CHIP) is a novel cardiovascular disease (CVD) risk factor in individuals without acute myeloid leukemia (AML). Objectives: The aim of this study was to...